Ralph Madeb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ralph Madeb has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
Dragan Golijanin
18 shared publicationsErdal Erturk
18 shared publicationsJoy Knopf
Department of Urology, University of Rochester School of Medicine and Dentistry, Rochester, New York
14 shared publicationsEdward M. Messing
Department of Urology, University of Rochester School of Medicine and Dentistry, Rochester, New York
9 shared publicationsIvelisse Vicente
8 shared publicationsJean V. Joseph
8 shared publications
Latest Publications
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4S)
PD66-01 IMMEDIATE POST TURB INTRAVESICAL GEMCITABINE: A COST COMPARISON BASED ON SWOG S0337
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4S)
PD66-01 IMMEDIATE POST TURB INTRAVESICAL GEMCITABINE: A COST COMPARISON BASED ON SWOG S0337
- 1 April 2011
- Published by SAGE Publications in Journal of Endourology
- Vol. 25 (4) , 573-577
The Impact of Robotics on Treatment of Localized Prostate Cancer and Resident Education in Rochester, New York
Background and Purpose: Robot-assisted radical prostatectomy (RARP) has been performed in Rochester, NY, since 2003. Currently, 10 area urologists perform RARP, and robotic training has become an important component of the residency. We present data describing the timeline for adoption, both in clinical practice and in the residency program. Materials and Methods: We reviewed the operating logs for all surgeons who were performing prostatectomies in all hospitals in Rochester, NY, from 2003 to 2007. We examined the influence RARP had on other treatments, including brachytherapy and cryotherapy. Surgical logs of graduating chief residents were also reviewed. Results: Eleven surgeons in Rochester regularly perform radical prostatectomy (10 perform primarily RARP, one performs only open prostatectomy). Three of the city's four hospitals have robotic systems. In 2003–2004, there were 30 open prostatectomies performed monthly and fewer than 10 performed robotically. By 2006, the trend was reversed, with 50 robot-assisted prostatectomies performed each month and fewer than 10 open prostatectomies (PConclusions: Since the introduction of surgical robotics, significant changes have been seen. The volume of radical prostatectomies performed by surgeons at institutions with robotics has increased; the volume at robot-free institutions has become nominal. There is a trend toward increased radiation therapy at robot-free institutions. While radical prostatectomies logged by graduating chief residents have increased, open prostatectomy experience is now minimal.
- 1 April 2011
- Published by SAGE Publications in Journal of Endourology
- Vol. 25 (4) , 573-577
The Impact of Robotics on Treatment of Localized Prostate Cancer and Resident Education in Rochester, New York
Background and Purpose: Robot-assisted radical prostatectomy (RARP) has been performed in Rochester, NY, since 2003. Currently, 10 area urologists perform RARP, and robotic training has become an important component of the residency. We present data describing the timeline for adoption, both in clinical practice and in the residency program. Materials and Methods: We reviewed the operating logs for all surgeons who were performing prostatectomies in all hospitals in Rochester, NY, from 2003 to 2007. We examined the influence RARP had on other treatments, including brachytherapy and cryotherapy. Surgical logs of graduating chief residents were also reviewed. Results: Eleven surgeons in Rochester regularly perform radical prostatectomy (10 perform primarily RARP, one performs only open prostatectomy). Three of the city's four hospitals have robotic systems. In 2003–2004, there were 30 open prostatectomies performed monthly and fewer than 10 performed robotically. By 2006, the trend was reversed, with 50 robot-assisted prostatectomies performed each month and fewer than 10 open prostatectomies (PConclusions: Since the introduction of surgical robotics, significant changes have been seen. The volume of radical prostatectomies performed by surgeons at institutions with robotics has increased; the volume at robot-free institutions has become nominal. There is a trend toward increased radiation therapy at robot-free institutions. While radical prostatectomies logged by graduating chief residents have increased, open prostatectomy experience is now minimal.
- 30 September 2010
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 184 (3) , 1225-1226
Re: Dipstick Pseudohematuria: Unnecessary Consultation and Evaluation: P. K. Rao, T. Gao, M. Pohl and J. S. Jones J Urol 2010; 183: 560–565
- 30 September 2010
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 184 (3) , 1225-1226
Re: Dipstick Pseudohematuria: Unnecessary Consultation and Evaluation: P. K. Rao, T. Gao, M. Pohl and J. S. Jones J Urol 2010; 183: 560–565
- Open Access
Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine?
BACKGROUND: Phase 3 clinical trials performed primarily outside the US demonstrate that intravesical instillation of chemotherapy immediately after transurethral resection of the bladder (TURB) decreases cancer recurrence rates. The authors sought to determine whether US urologists have adopted this practice, and its potential effect on costs of bladder cancer (BC) care.METHODS: By using 1997‐2004 MEDSTAT claims data, the authors identified patients with newly diagnosed BC who underwent cystoscopic biopsy or TURB, and those who received intravesical chemotherapy within 1 day after TURB. Economic consequences of this treatment compared with TURB alone were modeled using published efficacy estimates and Medicare reimbursements. The authors used a time horizon of 3 years and assumed that this treatment was given for all newly diagnosed low‐risk BC patients.RESULTS: Between 1997 and 2004, the authors identified 16,748 patients with newly diagnosed BC, of whom 14,677 underwent cystoscopic biopsy or TURB. Of these, only 49 (0.33%) received same‐day intravesical instillation of chemotherapy. From 1997 through 2004, there has been little change in the use of this treatment. The authors estimated a 3‐year savings of $538 to $690 (10% to 12%) per patient treated with TURB and immediate intravesical chemotherapy compared with TURB alone, reflecting a yearly national savings of $19.8 to $24.8 million.CONCLUSIONS: Instillation of intravesical chemotherapy immediately after TURB has not been embraced in the US. Adopting this policy would significantly lower the cost of BC care. Cancer 2009. © 2009 American Cancer Society.
Open AccessTreatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine?
BACKGROUND: Phase 3 clinical trials performed primarily outside the US demonstrate that intravesical instillation of chemotherapy immediately after transurethral resection of the bladder (TURB) decreases cancer recurrence rates. The authors sought to determine whether US urologists have adopted this practice, and its potential effect on costs of bladder cancer (BC) care.METHODS: By using 1997‐2004 MEDSTAT claims data, the authors identified patients with newly diagnosed BC who underwent cystoscopic biopsy or TURB, and those who received intravesical chemotherapy within 1 day after TURB. Economic consequences of this treatment compared with TURB alone were modeled using published efficacy estimates and Medicare reimbursements. The authors used a time horizon of 3 years and assumed that this treatment was given for all newly diagnosed low‐risk BC patients.RESULTS: Between 1997 and 2004, the authors identified 16,748 patients with newly diagnosed BC, of whom 14,677 underwent cystoscopic biopsy or TURB. Of these, only 49 (0.33%) received same‐day intravesical instillation of chemotherapy. From 1997 through 2004, there has been little change in the use of this treatment. The authors estimated a 3‐year savings of $538 to $690 (10% to 12%) per patient treated with TURB and immediate intravesical chemotherapy compared with TURB alone, reflecting a yearly national savings of $19.8 to $24.8 million.CONCLUSIONS: Instillation of intravesical chemotherapy immediately after TURB has not been embraced in the US. Adopting this policy would significantly lower the cost of BC care. Cancer 2009. © 2009 American Cancer Society.
- 20 May 2009
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (15) , 2443-2449
Grade and Stage at Presentation Do Not Predict Mortality in Patients With Bladder Cancer Who Survive Their Disease
Purpose: Our goal was to determine whether presenting grade and stage of bladder cancer (BC), which directly affect disease-specific survival, also influence time to and cause of non-BC deaths. Methods: Histology slides of all men who lived in Wisconsin age ≥ 50 years diagnosed with BC in 1988 were reviewed centrally, and time and cause of death as reported to the state's tumor registry were recorded. Competing risks analyses based on grade, tumor stage, and age at diagnosis were generated to correlate time and causes of death (BC or non-BC) with tumor histology and age at presentation. Results: Grade-stage categories were assigned to 509 patients with BC as follows: LGN = low grade (grade 1 or 2), nonmuscle invading (stage Ta or T1); HGN = high grade (grade 3 or carcinoma in situ), nonmucle invading (stage Ta, T1, or TIS); and INV = any grade, muscle invasive (≥ stage T2). Three hundred nine patients (60.7%) were LGN, 80 (15.7%) were HGN, and 120 (23.6%) were INV. Grade-stage category predicted overall (P = .0001) and BC-specific (P < .0001) mortality but not non-BC mortality (P = .72), with hazard ratios of 1.095 (95% CI, 0.783 to 1.531) for HGN versus LGN, 1.137 (95% CI, 0.799 to 1.617) for INV versus LGN, and 1.038 (95% CI, 0.670 to 1.607) for INV versus HGN. Age had a highly significant effect on overall and non-BC deaths (P < .0001) but only marginally predicted BC deaths (P = .054). Time to non-BC death did not differ significantly between grade-stage category (P = .12) or cause of death (P = .81). Conclusion: Grade-stage category at diagnosis predicts overall and BC mortality but not mortality from other causes. Thus, particularly for INV disease, because BC represents the major threat to life, aggressive therapies that have been shown to be effective are justified.
- 20 May 2009
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (15) , 2443-2449
Grade and Stage at Presentation Do Not Predict Mortality in Patients With Bladder Cancer Who Survive Their Disease
Purpose: Our goal was to determine whether presenting grade and stage of bladder cancer (BC), which directly affect disease-specific survival, also influence time to and cause of non-BC deaths. Methods: Histology slides of all men who lived in Wisconsin age ≥ 50 years diagnosed with BC in 1988 were reviewed centrally, and time and cause of death as reported to the state's tumor registry were recorded. Competing risks analyses based on grade, tumor stage, and age at diagnosis were generated to correlate time and causes of death (BC or non-BC) with tumor histology and age at presentation. Results: Grade-stage categories were assigned to 509 patients with BC as follows: LGN = low grade (grade 1 or 2), nonmuscle invading (stage Ta or T1); HGN = high grade (grade 3 or carcinoma in situ), nonmucle invading (stage Ta, T1, or TIS); and INV = any grade, muscle invasive (≥ stage T2). Three hundred nine patients (60.7%) were LGN, 80 (15.7%) were HGN, and 120 (23.6%) were INV. Grade-stage category predicted overall (P = .0001) and BC-specific (P < .0001) mortality but not non-BC mortality (P = .72), with hazard ratios of 1.095 (95% CI, 0.783 to 1.531) for HGN versus LGN, 1.137 (95% CI, 0.799 to 1.617) for INV versus LGN, and 1.038 (95% CI, 0.670 to 1.607) for INV versus HGN. Age had a highly significant effect on overall and non-BC deaths (P < .0001) but only marginally predicted BC deaths (P = .054). Time to non-BC death did not differ significantly between grade-stage category (P = .12) or cause of death (P = .81). Conclusion: Grade-stage category at diagnosis predicts overall and BC mortality but not mortality from other causes. Thus, particularly for INV disease, because BC represents the major threat to life, aggressive therapies that have been shown to be effective are justified.
- 19 May 2009
- Published by Springer Nature
- p. 93-103
Perioperative Intravesical Therapy
- 1 April 2009
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 181 (4S) , 191
THE CREATION OF A CYBER-HOSPITAL: A HEALTHCARE STRATEGY AND DELIVERY NETWORK FOR REGIONALIZATION OF UROLOGIC SPECIALTY CARE
- 1 April 2009
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 181 (4S) , 191
THE CREATION OF A CYBER-HOSPITAL: A HEALTHCARE STRATEGY AND DELIVERY NETWORK FOR REGIONALIZATION OF UROLOGIC SPECIALTY CARE
- 26 February 2008
- Published by Springer Nature
- p. 207-213
Policy Guidelines for Robot-Assisted Surgery in Urology
- 26 February 2008
- Published by Springer Nature
- p. 207-213
Policy Guidelines for Robot-Assisted Surgery in Urology